newsfilter
← Latest News
PR Newswire·

Braxia Scientific CEO, Chief Medical Officer Awarded $918,000 by Canadian Government to Study Benefits of Integrating Ketamine with Cognitive Behavioural Therapy to Reduce Suicidality

Innovative Ketamine clinical trial ranked in the 94th percentile by the CIHR peer review committee Suicidality remains second-leading cause of death among youth and young adults, and the 9th most common cause of death among Canadians TORONTO, July